Zydus Cadila and Hospira Inc., USA (now part of Pfizer Group)’s 50: 50 joint venture company--Zydus Hospira Oncology has received an Establishment Inspection Report (EIR) for manufacturing facility situated at Ahmedabad, from the US Food and Drug Administration (USFDA) which concluded that the inspection is closed and States that the inspection classification of this facility is 'Voluntary Action Indicated' (VAI). The manufacturing plant had completed the USFDA audit from April 5-12, 2018.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
